Spain court hears case against German maker of Thalidomide (Update)

A Madrid court on Monday heard Spain's first lawsuit against German firm Grunenthal, the manufacturer of the morning sickness drug thalidomide which caused birth defects in thousands of babies.

The lawsuit was filed by Avite, an association representing Spaniards born with severe defects after their mothers took the drug during their pregnancies.

The group is seeking compensation of 204 million euros ($276 million) from the company for its roughly 180 members.

Dozens of Spaniards born with defects caused by the drug, many in wheelchairs or on crutches, arrived at the court for the one-day trial carrying a sign reading simply "Justice".

The group said on its website that it hoped the "historic lawsuit (would) appease the suffering of Spanish victims, which began in their mothers' wombs and continues today, with the amputation of their arms and legs".

Thalidomide was originally marketed as a sedative, but from the late 1950s was prescribed to women around the world to combat morning sickness.

Many of the children of the mothers who took the drug were born with abnormally short limbs and in some cases without any arms, legs or hips. In late 1961 the drug was withdrawn from the British and German markets.

But it continued to be sold in other countries including Spain, Canada and Japan for several more months.

The drug is estimated to have caused deformities in 10,000-20,000 babies in some 40 countries.

Avite estimates that up to 3,000 babies may have been born with deformities in Spain because of the drug.

"If the verdict agrees with our complaint, the German firm Grunenthal will officially be considered for the first time in history as being responsible for what has happened," the association said on its website.

Grunenthal has refused to accept liability but last year it issued its first ever apology for the scandal, saying it was "very sorry" for its silence towards victims of the drug.

The company's lawyers rejected the compensation demand, arguing that the case had exceeded the statute of limitations.

"The events took place over 50 years ago, which leads us to believe that the legitimacy of any legal procedure could be seriously compromised given the time that has elapsed," the company said in a statement.

The company also said Spanish victims could seek aid through two German foundations and potentially "receive the same economic benefits" as German victims.

A ruling in the case is expected in three weeks.

add to favorites email to friend print save as pdf

Related Stories

Victims: Thalidomide sold in Spain post-withdrawal

May 08, 2013

(AP)—Spanish victims of thalidomide on Wednesday published documents they claim prove a German drug company kept distributing the notorious drug in Spain six months after it was taken off the market in other countries.

Australian wins millions in Thalidomide lawsuit

Jul 18, 2012

(AP) — An Australian woman born without arms and legs after her pregnant mother took the anti-morning sickness drug Thalidomide has reached a multimillion dollar settlement with the medicine's British distributor, her ...

Thalidomide maker 'ignored birth defects for years'

Jul 27, 2012

The German makers of thalidomide were warned of birth defects years before it was withdrawn and Australian distributors used pregnant women as the world's first test subjects, court papers alleged Friday.

Australian woman wins thalidomide hearing: court

Dec 19, 2011

A woman born without arms or legs on Monday won the right to have the class action she is leading against the firms behind thalidomide, a sedative blamed for birth defects, proceed in Australia.

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

User comments